相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Practice patterns of surgery for advanced ovarian cancer: analysis from international surveys
Soo Jin Park et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
Jodi A. McKenzie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
Jodi A. McKenzie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
Fernanda Musa et al.
GYNECOLOGIC ONCOLOGY (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman et al.
LANCET ONCOLOGY (2017)
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)
Christian Kurzeder et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial
Andres M. Poveda et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Bevacizumab as front-line treatment for newly diagnosed epithelial cancer
Antonio Gonzalez Martin et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)
Thomas J. Herzog et al.
GYNECOLOGIC ONCOLOGY (2011)
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
Jalid Sehouli et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase I/IIa Study of Combination Chemotherapy with CKD-602 and Cisplatin in Patients with Recurrent Epithelial Ovarian Cancer
Hee Seung Kim et al.
NATURAL COMPOUNDS AND THEIR ROLE IN APOPTOTIC CELL SIGNALING PATHWAYS (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer
Hyo-Pyo Lee et al.
GYNECOLOGIC ONCOLOGY (2008)
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis
S Okamura et al.
MOLECULAR CELL (2001)
Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study
WP McGuire et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
